JP2017528117A5 - - Google Patents

Download PDF

Info

Publication number
JP2017528117A5
JP2017528117A5 JP2016575026A JP2016575026A JP2017528117A5 JP 2017528117 A5 JP2017528117 A5 JP 2017528117A5 JP 2016575026 A JP2016575026 A JP 2016575026A JP 2016575026 A JP2016575026 A JP 2016575026A JP 2017528117 A5 JP2017528117 A5 JP 2017528117A5
Authority
JP
Japan
Prior art keywords
antibody molecule
multispecific antibody
molecule according
domain
dsfv
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2016575026A
Other languages
English (en)
Japanese (ja)
Other versions
JP2017528117A (ja
Filing date
Publication date
Priority claimed from GBGB1411420.1A external-priority patent/GB201411420D0/en
Application filed filed Critical
Publication of JP2017528117A publication Critical patent/JP2017528117A/ja
Publication of JP2017528117A5 publication Critical patent/JP2017528117A5/ja
Pending legal-status Critical Current

Links

JP2016575026A 2014-06-26 2015-06-25 多重特異性抗体コンストラクト Pending JP2017528117A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
GBGB1411420.1A GB201411420D0 (en) 2014-06-26 2014-06-26 Antibody constructs
GB1411420.1 2014-06-26
PCT/EP2015/064450 WO2015197789A1 (en) 2014-06-26 2015-06-25 Multi-specific antibody constructs

Publications (2)

Publication Number Publication Date
JP2017528117A JP2017528117A (ja) 2017-09-28
JP2017528117A5 true JP2017528117A5 (enExample) 2018-08-02

Family

ID=51410201

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2016575026A Pending JP2017528117A (ja) 2014-06-26 2015-06-25 多重特異性抗体コンストラクト

Country Status (10)

Country Link
US (1) US20170198062A1 (enExample)
EP (1) EP3161008B1 (enExample)
JP (1) JP2017528117A (enExample)
CN (1) CN106459217A (enExample)
BR (1) BR112016030424A2 (enExample)
CA (1) CA2953638A1 (enExample)
ES (1) ES2763525T3 (enExample)
GB (1) GB201411420D0 (enExample)
RU (1) RU2710730C2 (enExample)
WO (1) WO2015197789A1 (enExample)

Families Citing this family (26)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US10752676B2 (en) * 2011-09-16 2020-08-25 Ucb Biopharma Sprl Neutralising antibodies to the major exotoxins TCDA and TCDB of Clostridium difficile
GB201409558D0 (en) 2014-05-29 2014-07-16 Ucb Biopharma Sprl Method
GB201412659D0 (en) 2014-07-16 2014-08-27 Ucb Biopharma Sprl Molecules
GB201412658D0 (en) 2014-07-16 2014-08-27 Ucb Biopharma Sprl Molecules
GB201601075D0 (en) 2016-01-20 2016-03-02 Ucb Biopharma Sprl Antibodies molecules
GB201601073D0 (en) 2016-01-20 2016-03-02 Ucb Biopharma Sprl Antibodies
GB201601077D0 (en) 2016-01-20 2016-03-02 Ucb Biopharma Sprl Antibody molecule
GB201521393D0 (en) 2015-12-03 2016-01-20 Ucb Biopharma Sprl Antibodies
GB201521382D0 (en) 2015-12-03 2016-01-20 Ucb Biopharma Sprl Antibodies
GB201521389D0 (en) 2015-12-03 2016-01-20 Ucb Biopharma Sprl Method
GB201521391D0 (en) 2015-12-03 2016-01-20 Ucb Biopharma Sprl Antibodies
GB201521383D0 (en) 2015-12-03 2016-01-20 Ucb Biopharma Sprl And Ucb Celltech Method
SG11201909160WA (en) 2017-04-11 2019-10-30 Inhibrx Inc Multispecific polypeptide constructs having constrained cd3 binding and methods of using the same
CN109970856B (zh) 2017-12-27 2022-08-23 信达生物制药(苏州)有限公司 抗lag-3抗体及其用途
KR20200118423A (ko) * 2018-01-08 2020-10-15 난징 레전드 바이오테크 씨오., 엘티디. 다중특이성 항원 결합 단백질 및 이의 사용 방법
WO2019200022A1 (en) 2018-04-11 2019-10-17 Inhibrx, Inc. Multispecific polypeptide constructs having constrained cd3 binding and related methods and uses
TW202035451A (zh) 2018-07-24 2020-10-01 美商英伊布里克斯公司 含有受限cd3結合域及受體結合區之多重特異性多肽構築體及其使用方法
WO2020076977A2 (en) 2018-10-11 2020-04-16 Inhibrx, Inc. Dll3 single domain antibodies and therapeutic compositions thereof
GB201919062D0 (en) 2019-12-20 2020-02-05 Ucb Biopharma Sprl Antibody
GB201919058D0 (en) * 2019-12-20 2020-02-05 Ucb Biopharma Sprl Multi-specific antibodies
GB201919061D0 (en) 2019-12-20 2020-02-05 Ucb Biopharma Sprl Multi-specific antibody
GB202001447D0 (en) 2020-02-03 2020-03-18 Ucb Biopharma Sprl Antibodies
EP4114373A4 (en) * 2020-03-03 2024-05-01 Systimmune, Inc. ANTI-CD19 ANTIBODIES AND THEIR METHODS OF USE AND PREPARATION
CA3175034A1 (en) 2020-03-27 2021-09-30 UCB Biopharma SRL Autonomous knob domain peptides
EP4255926A1 (en) 2020-12-07 2023-10-11 UCB Biopharma SRL Multi-specific antibodies and antibody combinations
GB202111905D0 (en) 2021-08-19 2021-10-06 UCB Biopharma SRL Antibodies

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
RU2246538C2 (ru) * 1998-05-20 2005-02-20 Чугаи Сейяку Кабусики Кайся Способ и набор для выявления гена, кодирующего мембраносвязанный белок, вектор (варианты)
TW200732350A (en) * 2005-10-21 2007-09-01 Amgen Inc Methods for generating monovalent IgG
JP5592792B2 (ja) * 2007-09-26 2014-09-17 ユセベ ファルマ ソシエテ アノニム 二重特異性抗体の融合体
US8193321B2 (en) * 2008-09-03 2012-06-05 Genentech, Inc. Multispecific antibodies
BRPI0919382A2 (pt) * 2008-09-26 2016-01-05 Roche Glycart Ag anticorpos bi-específicos anti-egfr/anti-igf-1r
SG177560A1 (en) * 2009-07-06 2012-03-29 Hoffmann La Roche Bi-specific digoxigenin binding antibodies
RU2013110875A (ru) * 2010-08-24 2014-09-27 Ф.Хоффманн-Ля Рош Аг БИСПЕЦИФИЧЕСКИЕ АНТИТЕЛА, СОДЕРЖАЩИЕ СТАБИЛИЗИРОВАННЫЙ ДИСУЛЬФИДОМ ФРАГМЕНТ Fv
EP2543680A1 (en) * 2011-07-07 2013-01-09 Centre National de la Recherche Scientifique Multispecific mutated antibody Fab fragments
EP2825559B1 (en) * 2012-03-13 2019-02-27 Novimmune SA Readily isolated bispecific antibodies with native immunoglobulin format

Similar Documents

Publication Publication Date Title
JP2017528117A5 (enExample)
RU2017102312A (ru) Конструкции мультиспецифичных антител
RU2017102193A (ru) Конструкции полиспецифических антител
JP2019506841A5 (enExample)
JP2017006120A5 (enExample)
RU2015129762A (ru) ОДНОЛИНКЕРНЫЕ АНТИТЕЛА FabFv И СПОСОБЫ ИХ ПОЛУЧЕНИЯ
JP2018127467A5 (enExample)
JP2014505463A5 (enExample)
JP2020503891A5 (enExample)
JP2016521688A5 (enExample)
JP2020503001A5 (enExample)
JP2017506217A5 (enExample)
HRP20161656T4 (hr) Sredstva za vezanje na cd33
JP2016502515A5 (enExample)
JP2019534277A5 (enExample)
EA201991099A1 (ru) Антитела против cd73 и их применение
HRP20240719T1 (hr) Kimerna i humanizirana monoklonska protutijela protiv ljudskog ctla4 i njihova upotreba
JP2016529215A5 (enExample)
HRP20220111T1 (hr) Protutijela protiv pd-1
AR103868A1 (es) Anticuerpos anti-cd47 como agentes terapéuticos
HRP20240495T1 (hr) Anti-garp antitijelo
JP2017529067A5 (enExample)
EA201590986A1 (ru) Антитела к ceacam5 и их применения
EA201690447A1 (ru) БИСПЕЦИФИЧЕСКИЕ МОНОВАЛЕНТНЫЕ ДИАТЕЛА, КОТОРЫЕ СПОСОБНЫ СВЯЗЫВАТЬСЯ С gpA33 И CD3, И ИХ ПРИМЕНЕНИЯ
RU2016129894A (ru) Ковалентно связанные конъюгаты хеликар-антитело против хеликара и их применения